Bioresearch Online News

New Brunswick Scientific Announces New Large-Capacity ULT Freezer

Mon, 06 Sep 2010 06:56:00 GMT

New Brunswick Scientific has added a new large-capacity, upright ultra-low temperature (-86�C) freezer to its expansive line, capable of storing up to 48,000 samples.

BMG LABTECH Introduces A Revolution In Absorbance Reading - SPECTROstar Nano

Sat, 04 Sep 2010 03:54:00 GMT

Experience the future of microplate reader technology today with the new SPECTROstar Nano.

Tibotec Pharmaceuticals Seeks European Marketing Authorization For Investigational Once-Daily HIV Treatment TMC278

Fri, 03 Sep 2010 05:51:00 GMT

Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV.

ForteBio Announces Launch Of Protein G Biosensor For Use On Company's Octet® Instruments

Fri, 03 Sep 2010 05:12:00 GMT

ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its Dip and Read™ Protein G biosensor for rapid detection and quantification of numerous types of mammalian immunoglobulin (IgG), an antibody molecule, from solution.

Lord Lieutenant Presents 2010 Queen's Award To Malvern Instruments

Fri, 03 Sep 2010 05:09:00 GMT

Sir Michael Brinton, the Lord Lieutenant of Worcestershire, today formally presented the 2010 Queen's Award for Enterprise in Innovation to materials characterization company Malvern Instruments in a ceremony held at its UK headquarters and attended by employees from all parts of the organisation.

Radient Pharmaceuticals Resumes Collaboration To Advance Its Onko-Sure® In Vitro Diagnostic Cancer Test In The USA

Thu, 02 Sep 2010 13:24:59 GMT

Radient Pharmaceuticals Corporation (RPC) /quotes/comstock/14*!rpc/quotes/nls/rpc (RPC 0.68, +0.00, +0.03%) announced today it has resumed collaborations with Mayo Collaborative Services, Inc. to conduct a clinical study for the validation of RPC's US FDA-approved Onko-Sure(R) in vitro diagnostic (IVD) cancer test as a useful tool in colorectal cancer (CRC) recurrence and treatment monitoring.

Addex Drug-Candidate Effective In Alzheimer's Disease Model

Thu, 02 Sep 2010 13:10:18 GMT

Allosteric modulation company Addex Pharmaceuticals Ltd (SIX: ADXN) announced today that it has observed efficacy in a model of Alzheimer's disease using a recently discovered orally-available drug-candidate. The proprietary molecule specifically inhibits a receptor subtype called the metabotropic glutamate receptor 2 (mGluR2) via negative allosteric modulation (NAM). An Addex mGluR2 NAM is scheduled to enter Phase I clinical testing in healthy volunteers during 2011.

Halozyme Begins Phase 2 Clinical Trials With Insulin Analogs Lispro and Aspart With rHuPH20 In Type 1 And Type 2 Diabetes

Thu, 02 Sep 2010 12:10:47 GMT

Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog�, and insulin lispro, the active ingredient in Humalog�.

QRxPharma Announces Interim Analysis Of Final Pivotal Phase 3 Study For MoxDuo®IR

Thu, 02 Sep 2010 11:38:35 GMT

QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission. The analysis indicated the planned sample size of 140 patients has greater than 90% power to detect differences of analgesic effect, indicating there is no need to enrol additional patients.

Spectrum Laboratories Introduces KrosFlo� Research IIi Tangential Flow Filtration System

Wed, 01 Sep 2010 14:44:03 GMT

Spectrum Laboratories, Inc. introduces the new KrosFlo Research IIi Tangential Flow Filtration (TFF) System. This updated system-ideal for R&D scale microfiltration and ultrafiltration processing-comes with the Digital Pressure Monitor integrated into the peristaltic pump.

Agensys, An Affiliate Of Astellas, Announces Initiation Of Phase I Clinical Trial Of AGS-16M8F For Renal Cancer

Wed, 01 Sep 2010 12:25:00 GMT

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer.

Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine

Wed, 01 Sep 2010 10:00:00 GMT

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH), for advanced development of the company's third generation anthrax vaccine candidate.

GreenVax Selects Xcellerex XDR Single-Use Bioreactors For New Vaccine And Biotherapeutics Program

Tue, 31 Aug 2010 12:30:00 GMT

Xcellerex, Inc. announced today that Project GreenVax has agreed to acquire XDR GMP single-use production bioreactors from Xcellerex. The systems will be deployed in a new facility currently under construction in Bryan, Texas.

BTG Plc: Agreement With Nycomed US Inc.

Tue, 31 Aug 2010 09:50:00 GMT

BTG plc, the specialty pharmaceuticals company, recently announces that it has signed an agreement with Nycomed US Inc. concerning the accelerated transition to BTG on 1 October 2010 of marketing rights to CroFab (Crotalidae Polyvalent Immune Fab (Ovine), an antivenom, and DigiFab (Digoxin Immune Fab (Ovine), for treating patients with life-threatening digoxin toxicity or overdose.

Vital Parameters Kept Under Surveillance

Tue, 31 Aug 2010 04:03:00 GMT

This electro-optical module is a solution for original equipment manufacturers (OEM) for customized monitoring devices. As for its small footprint, it can easily be integrated and, assembled according to ISO 9001:2008, it guarantees a precise and non-invasive CO2 measurement.

KYTHERA And Bayer Dermatology Unit Intendis Enter Licensing And Development Agreement For Adipolytic Agent ATX-101

Mon, 30 Aug 2010 16:30:00 GMT

KYTHERA Biopharmaceuticals, Inc. ("KYTHERA") and Intendis, Bayer HealthCare's dermatology business, today announced that they have entered into a licensing agreement granting Intendis rights to KYTHERA's lead product candidate, ATX-101, outside of the US and Canada.

BARDA Funds Drug Development For Biothreats, Antibiotic Resistance

Mon, 30 Aug 2010 15:15:00 GMT

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) today awarded a contract to develop an antibiotic that could be used against possibly two types of bioterrorism as well as common infections that are becoming resistant to antibiotics.

Lineagen, Inc. Closes $5M To Complete $10.8M Series A Round

Mon, 30 Aug 2010 13:00:00 GMT

Lineagen, Inc., a developer of innovative genomic tests and services for the screening, evaluation and diagnosis of complex disorders and diseases including autism spectrum disorders and others, today announced that PrairieGold Venture Partners has joined Lineagen's existing institutional venture investors in a further $5M closing of its Series A round, which completes Lineagen's $10.8M Series A financing.

Nanotherapeutics Submits Investigational New Drug Application To FDA For Clinical Testing Of Oral Drug To Treat Radiation Exposure

Mon, 30 Aug 2010 12:00:00 GMT

Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid).

FDA Update: Week Of August 30, 2010

Mon, 30 Aug 2010 12:00:00 GMT

According to an AP report on Businessweek.com, federal regulators are trying to determine whether Novartis' Parkinson's disease drug Stalevo causes an increased risk of heart attacks or strokes.